Opicapone in Parkinson’s disease: a profile of its use Lesley J. Scott Adis Drug Q&A 12 June 2017 Pages: 303 - 310
Pylera® (bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride) in the eradication of Helicobacter pylori infection: a profile of its use in Europe Katherine A. Lyseng-Williamson Adis Drug Q&A 09 June 2017 Pages: 311 - 320
Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU Kate McKeageKatherine A. Lyseng-Williamson Adis Drug Q&A 02 June 2017 Pages: 321 - 325
Treat androgenetic alopecia with antiandrogens, as well as other pharmacological and non-pharmacological interventions Adis Medical Writers Disease Management 26 April 2017 Pages: 326 - 330
Recognize and treat travel-related skin diseases in returning travellers and recommend preventative measures to future travellers Adis Medical Writers Disease Management 17 March 2017 Pages: 331 - 336
First reports of adverse drug reactions Drug Reactions and Interactions 06 June 2017 Pages: 337 - 338
Be aware that the use of tobacco, cannabinoids and smoking cessation may result in pharmacokinetic interactions with other drugs Adis Medical Writers Drug Reactions and Interactions 05 May 2017 Pages: 339 - 344
What underlies the unconscious negative attitude of healthcare professionals towards patient-reported drug allergies? Christopher J. Young Commentary 06 June 2017 Pages: 345 - 347
A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis Sumit KunwarAshok Raj DevkotaPrabhat Adhikari Review Article 04 May 2017 Pages: 348 - 360
